PURPOSE: A clinical trial was designed to test the hypothesis that a psychological intervention could reduce the risk of cancer recurrence. Newly diagnosed regional breast cancer patients (n = 227) were randomized to the intervention-with-assessment or the assessment-only arm. The intervention had positive psychological, social, immune, and health benefits, and after a median of 11 years the intervention arm was found to have reduced the risk of recurrence (hazard ratio, 0.55; P = 0.034). In follow-up, we hypothesized that the intervention arm might also show longer survival after recurrence. If observed, we then would examine potential biobehavioral mechanisms. EXPERIMENTAL DESIGN: All patients were followed; 62 recurred. Survival analyses included all 62. Upon recurrence diagnosis, those available for further biobehavioral study were accrued (n = 41, 23 intervention and 18 assessment). For those 41, psychological, social, adherence, health, and immune (natural killer cell cytotoxicity, T-cell proliferation) data were collected at recurrence diagnosis and 4, 8, and 12 months later. RESULTS: Intent-to-treat analysis revealed reduced risk of death following recurrence for the intervention arm (hazard ratio, 0.41; P = 0.014). Mixed-effects follow-up analyses with biobehavioral data showed that all patients responded with significant psychological distress at recurrence diagnosis, but thereafter only the intervention arm improved (P values < 0.023). Immune indices were significantly higher for the intervention arm at 12 months (P values < 0.017). CONCLUSIONS: Hazards analyses augment previous findings in showing improved survival for the intervention arm after recurrence. Follow-up analyses showing biobehavioral advantages for the intervention arm contribute to our understanding of how improved survival was achieved. (c) 2010 AACR.
RCT Entities:
PURPOSE: A clinical trial was designed to test the hypothesis that a psychological intervention could reduce the risk of cancer recurrence. Newly diagnosed regional breast cancerpatients (n = 227) were randomized to the intervention-with-assessment or the assessment-only arm. The intervention had positive psychological, social, immune, and health benefits, and after a median of 11 years the intervention arm was found to have reduced the risk of recurrence (hazard ratio, 0.55; P = 0.034). In follow-up, we hypothesized that the intervention arm might also show longer survival after recurrence. If observed, we then would examine potential biobehavioral mechanisms. EXPERIMENTAL DESIGN: All patients were followed; 62 recurred. Survival analyses included all 62. Upon recurrence diagnosis, those available for further biobehavioral study were accrued (n = 41, 23 intervention and 18 assessment). For those 41, psychological, social, adherence, health, and immune (natural killer cell cytotoxicity, T-cell proliferation) data were collected at recurrence diagnosis and 4, 8, and 12 months later. RESULTS: Intent-to-treat analysis revealed reduced risk of death following recurrence for the intervention arm (hazard ratio, 0.41; P = 0.014). Mixed-effects follow-up analyses with biobehavioral data showed that all patients responded with significant psychological distress at recurrence diagnosis, but thereafter only the intervention arm improved (P values < 0.023). Immune indices were significantly higher for the intervention arm at 12 months (P values < 0.017). CONCLUSIONS: Hazards analyses augment previous findings in showing improved survival for the intervention arm after recurrence. Follow-up analyses showing biobehavioral advantages for the intervention arm contribute to our understanding of how improved survival was achieved. (c) 2010 AACR.
Authors: P J Goodwin; M Leszcz; M Ennis; J Koopmans; L Vincent; H Guther; E Drysdale; M Hundleby; H M Chochinov; M Navarro; M Speca; J Hunter Journal: N Engl J Med Date: 2001-12-13 Impact factor: 91.245
Authors: Maria Liljefors; Bo Nilsson; Anna-Lena Hjelm Skog; Peter Ragnhammar; Håkan Mellstedt; Jan-Erik Frödin Journal: Int J Cancer Date: 2003-07-10 Impact factor: 7.396
Authors: David W Kissane; Sidney Bloch; Graeme C Smith; Patricia Miach; David M Clarke; Jillian Ikin; Anthony Love; Nadia Ranieri; Dean McKenzie Journal: Psychooncology Date: 2003-09 Impact factor: 3.894
Authors: William E Carson; Charles L Shapiro; Timothy R Crespin; Lisa M Thornton; Barbara L Andersen Journal: Clin Cancer Res Date: 2004-05-15 Impact factor: 12.531
Authors: Brittany M Brothers; Kristen M Carpenter; Rebecca A Shelby; Lisa M Thornton; Georita M Frierson; Kyle L Patterson; Barbara L Andersen Journal: Transl Behav Med Date: 2015-03 Impact factor: 3.046
Authors: Lisa M Thornton; Anna O Levin; Caroline S Dorfman; Neha Godiwala; Carolyn Heitzmann; Barbara L Andersen Journal: Psychooncology Date: 2013-10-14 Impact factor: 3.894
Authors: Barbara L Andersen; Neha Godiwala Goyal; Travis D Westbrook; Brenden Bishop; William E Carson Journal: Clin Cancer Res Date: 2016-07-12 Impact factor: 12.531
Authors: Lyn W Freeman; Rebecca White; Chelsea G Ratcliff; Sue Sutton; Mary Stewart; J Lynn Palmer; Judith Link; Lorenzo Cohen Journal: Psychooncology Date: 2014-08-22 Impact factor: 3.894
Authors: Abby R Rosenberg; Miranda C Bradford; Krysta S Barton; Nicole Etsekson; Elizabeth McCauley; J Randall Curtis; Joanne Wolfe; K Scott Baker; Joyce P Yi-Frazier Journal: Pediatr Blood Cancer Date: 2018-09-30 Impact factor: 3.167